Survey

Help us improve Glivec.com. Please take our short survey.

TAKE SURVEY
Printer-Friendly Version | Email This Page

Common Patient Questions

1 2 3


The following questions will help you prepare to respond to typical patient concerns and queries about Glivec® (imatinib) and its role in CML (chronic myeloid leukaemia) and GIST (gastrointestinal stromal tumour) treatment.

1. Frequently Asked Questions in CML
          a. Questions About CML
          b. Questions About Glivec (imatinib) in CML

2. Frequently Asked Questions in GIST
          a. Questions About GIST
          b. Questions About Glivec (imatinib) in GIST

Find out about efficacy, dosage, and safety in Prescribing Glivec.

GIPAP Count

GIPAP is open in about 80 countries. As of November 30, 2007 the total number of patients reached was 19,378.